Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brookfield Infrastructure Partners LP (BIP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Brookfield Infrastructure Partners LPTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Brookfield Infrastructure Partners LP vs Zimmer Biomet Holdings Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Zimmer Biomet Holdings Inc trades at $90.42 (market cap $17.61B). The key difference: Brookfield Infrastructure Partners LP and Zimmer Biomet Holdings Inc are close in size by market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.77%). Which is the better fit depends on your goals.

BIPZBH
Market Cap
$17.38B$17.61B
Sector
IndustrialsHealth
52-Week High
$40.08$107.71
52-Week Low
$29.81$79.58
Enterprise Value
$79.06B$24.66B
Dividend Yield
4.77%1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brookfield Infrastructure Partners LP

Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.

BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.

ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brookfield Infrastructure Partners LP

Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.

Read more on BIP

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH